With a view to reducing the risk of child sexual abuse, Swedish researchers are planning to examine the effectiveness of a drug to prevent paedophiles from committing crime.
In a unique trial, The Karolinska Institute in Stockholm is using a testosterone-suppressing drug as a preventative measure on patients seeking help for paedophile fantasies, The Independent reported.
Patients at the Karolinska Institute who have had paedophilic fantasies but have not acted on them are being given a drug normally used to treat advanced prostate cancer to see if it reduces the risk of them sexually abusing a child.
Christoffer Rahm is the initiator and the principal investigator of this treatment study.
"This project aims to reduce the number of child sexual abuse cases. In order to achieve this we are exploring one of the few feasible strategies, to establish a preventive, effective and risk reducing treatment for men with paedophilic disorder that is also tolerable for the patient," the researchers wrote on the British science crowdfunding platform Walacea for raising a portion of the research fund.
"In addition to providing better treatment options to patients with paedophilic disorder we aim to introduce a reliable objective risk assessment tool. We want to shift focus from what happens when the damage is already done, and instead focusing on the earlier phase, to intervene before the child sexual abuse happens in the first place," they added.
This crowdfunding campaign that closes on July 7, 2016 plans to raise funds for the first part of this project, the clinical trial to test the effectiveness of the drug degarelix.
In this trial of 60 patients, 30 receive an injection of the drug Degarelix and the other 30 are given a placebo.
Trial volunteers will be studied for the next two to three years, the report added.
--IANS
gb/dg
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
